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Pharyngeal pumpingOur objective was to determine if the resistance mechanism to moxidectin (MOX) is similar of that to
ivermectin (IVM) and involves P-glycoproteins (PGPs). Several Caenorhabditis elegans strains were used:
an IVM and MOX sensitive strain, 13 PGP deletion strains and the IVM-R strain which shows synthetic
resistance to IVM (by creation of three point mutations in genes coding for a-subunits of glutamate gated
chloride channels [GluCls]) and cross-resistance to MOX. These strains were used to compare expression
of PGP genes, measure motility and pharyngeal pumping phenotypes and evaluate the ability of com-
pounds that inhibit PGP function to potentiate sensitivity or reverse resistance to MOX. The results sug-
gest that C. elegans may use regulation of PGPs as a response mechanism to MOX. This was indicated by
the over-expression of several PGPs in both drug sensitive and IVM-R strains and the signiﬁcant changes
in phenotype in the IVM-R strain in the presence of PGP inhibitors. However, as the inhibitors did not
completely disrupt expression of the phenotypic traits in the IVM-R strain, this suggests that there likely
are multiple avenues for MOX action that may include receptors other than GluCls. If MOX resistance was
mediated solely by GluCls then exposure of the IVM-R strain to PGP inhibitors should not have affected
sensitivity to MOX. Targeted gene deletions showed that protection of C. elegans against MOX involves
complex mechanisms and depends on the PGP gene family, particularly PGP-6. While the results pre-
sented are similar to others using IVM, there were some important differences observed with respect
to PGPs which may play a role in the disparities seen in the characteristics of resistance to IVM and
MOX. The similarities are of concern as parasites resistant to IVM show some degree but not complete
cross-resistance to MOX; this could impact nematodes that are resistant to IVM.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction milbemycins, however the bisoleandrosyloxy substituent locatedThe macrocyclic lactones which include the avermectins (e.g.,
ivermectin [IVM]) and milbemycins (e.g., moxidectin [MOX]) are
natural fermentation products of soil-dwelling microorganisms
which have been commercialized and are used to control nema-
tode infections (Demain and Sanchez, 2009). The avermectins are
produced by Streptomyces avermilitis and IVM is arguably the most
widely used drug in this group. MOX is the most commonly used
milbemycin due to its versatility, stability, high potency and safety
(Prichard et al., 2012). It is a semisynthetic methoxime derivative
of nemadectin, a fermentation product of Streptomyces cyanogri-
seus subsp. noncyanogenus (Shoop et al., 1995). This There are sev-
eral differences in the chemical structure of the avermectins andat the C-13 position on the macrolide ring of avermectins, which
is unsubstituted in the milbemycins, is the most notable
(Campbell, 1989). Other differences include several different alkyl
substituents at C-25 in both groups (Shoop et al., 1995) and the
C-23 methoxime in MOX (Prichard et al., 2012). IVM was the ﬁrst
macrocyclic lactone that was approved for use in both animals
and humans and others (e.g., abamectin, emamectin and MOX)
were subsequently commercialized for the veterinary market.
IVM remains the sole macrocyclic lactone registered for use in
humans to treat ﬁlarioid, strongyloides and mite infections
(Omura and Crump, 2004). However, MOX has undergone Phase
1, 2 and 3 clinical trials against human onchocerciasis (Prichard
et al., 2012).
Despite the structural differences between the avermectins and
milbemycins, the primary mechanism of action is similar and
results in paralysis and death of nematodes through activation of
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cells (Cully et al., 1994; Dent et al., 1997; Hibbs and Gouaux,
2011) and through effects on gamma-aminobutyric acid (GABA)
receptors (Feng et al., 2002). Activation of these chloride channels
results in paralysis of the pharynx and somatic muscle in nema-
todes (Prichard et al., 2012). In mammals, the macrocyclic lactones
can induce neurotoxicity by acting on GABA receptors in the cen-
tral nervous system (Ménez et al., 2012).
Although both IVM and MOX act on GluCl and GABA receptors
there are signiﬁcant differences in their effects at different chloride
channels, in different invertebrate species. Some of these differ-
ences have been summarized in Prichard et al. (2012). For example,
in IVM selected strains of Haemonchus contortus, pharyngeal
pumping was altered by IVM, but remained unchanged in the pres-
ence of MOX (Paiement et al., 1999). In Caenorhabditis elegans
exposed to a gradient (ranging from 0 to 5000 nM) of IVM and
MOX, differences were observed in pharyngeal pumping, larval
development and motility of wild type and IVM resistant worms.
This study concluded that the product of the glc-2 gene may play
a role in sensitivity to MOX, but not to IVM, while the products
of avr-14, avr-15 and glc-1 may be important for the effects of
IVM, but less so for MOX (Ardelli et al., 2009). Similarly, there
are differences in the action of IVM and MOX on mammalian GABA
receptors (Ménez et al., 2012).
Parasites resistant to IVM show some degree but not complete
cross-resistance to MOX (see review by Prichard et al., 2012). A
recent study suggested a role for the ABC systems proteins P-glyco-
proteins (PGPs) (Ardelli and Prichard, 2013) in IVM resistance. In
this study, signiﬁcant changes in movement and pharyngeal
pumping were noted in an IVM resistant strain of C. elegans
(Dent et al., 2000) in the presence of compounds known to inhibit
or disrupt PGP function. However, the compounds did not com-
pletely disrupt movement and pharyngeal pumping, indicating
that there are probably multiple avenues for IVM action that
include receptors other than the GluCls that had been silenced.
Because there is a degree of cross-resistance between IVM and
MOX, but usually not complete cross-resistance (Prichard et al.,
2012), a better understanding of mechanisms of cross-resistance
is required, particularly as clinical trials are underway to assess
the efﬁcacy of MOX against Onchocerca volvulus (WHO, 2009), a
parasite for which IVM resistance has been conﬁrmed (Osei-
Atweneboana et al., 2007, 2011). The objective of this study was
to determine if the resistance mechanism of MOX is similar to that
of IVM and involves PGPs. To assess this we used several strains of
C. elegans including an IVM and MOX sensitive wild-type strain, 13
PGP deletion strains and a triple IVM receptor (avr-14/avr-15/glc-1)
knock-out strain showing synthetic resistance to IVM (Dent et al.,
2000) and cross-resistance to MOX (Ardelli et al., 2009). These
strains were treated with MOX and used to (1) compare the gene
expression signatures of 15 PGPs in the wild-type and resistant
strains following treatment; (2) measure motility and pharyngeal
pumping phenotypes in the wild-type, resistant and PGP deletion
strains before and after treatment; and (3) evaluate the ability of
compounds that are competitive inhibitors, or that block PGP func-
tion directly, to potentiate sensitivity or reverse resistance to MOX
in the wild type, IVM resistant and PGP deletion strains.2. Materials and methods
2.1. Maintenance of C. elegans strains
C. elegans were grown on NGM agar plates seeded with Esche-
richia coli OP50 as described (Ardelli and Prichard, 2013). The Bris-
tol N2 (wild-type), the synthetically resistant avr-14/avr-15/glc-1
triple mutant (designated IVM-R) and the PGP deletion strainsNL132 (pgp-1), GH378 (pgp-2), RB2349 (pgp-3), VC2159 (pgp-4),
RB959 (pgp-5), RB104 (pgp-6 and pgp-7), RB1916 (pgp-8), RB1045
(pgp-10), VC26 (pgp-12), RB894 (pgp-13), RB2008 (pgp-14), and
RB1041 (pgp-15) were used. The IVM-R strain contains a point
mutation in each of the GluCl a-subunits avr-14, avr-15 and glc-
1. These point mutations make the IVM-R strain approximately
4000-fold less sensitive to IVM and it was considered resistant to
IVM (Dent et al., 2000) and cross-resistant to MOX (Ardelli and
Prichard, 2008; Ardelli et al., 2009). Bioinformatic and expression
analysis of the PGP deletion strains indicated that they are func-
tional nulls, homozygous, hermaphrodite stocks that are superﬁ-
cially wild type. The strains were out-crossed and cultures were
synchronized prior to use.
2.2. Drug exposure
MOX and the PGP inhibitors R(+)-verapamil monohydrochlo-
ride monohydrate, vincristine sulfate, doxorubicin, etoposide, acti-
nomycin D, colchicine, vinblastine, rhodamine 123, quinidine,
quinine and forskolin were purchased from Sigma Life Science.
All compounds were dissolved in a ﬁnal concentration of 0.25 v/v
of dimethylsulfoxide (DMSO). The concentrations of MOX and
inhibitors are indicated within each experiment. In addition to
being inhibitors of PGP proteins, these inhibitors have an addi-
tional mechanism of action including targeting of ion channels
(i.e., verapamil, quinidine, quinine), tubulin (i.e., vincristine, vin-
blastine, colchicine), DNA replication (i.e., actinomycin, doxorubi-
cin, etoposide) and enzymes (i.e., rhodamine, forskolin) (Palmiera
et al., 2012).
2.3. Effects of MOX on PGP gene expression
The innate defense mechanism conferred by PGP against toxins
in mammals is often observed as changes in expression levels
(Chin et al., 1990). To determine if PGP expression responds in a
similar manner in C. elegans, the wild-type and IVM-R strain were
treated with MOX and the transcriptional proﬁles of the 15 PGP
genes were measured to determine if treatment would result in
changes in gene expression. Previous studies that evaluated GluCls,
PGP and MRP expression in C. elegans after IVM treatment used a
ﬁnal concentration of 2.5 nM the same concentration was used in
this study for comparative purposes (Ardelli and Prichard, 2008,
2013; Ardelli et al., 2009). The method used for expression analysis
has been described (Ardelli et al., 2010). The primer sequences for
the PGP genes and the control genes have been reported (Ardelli
and Prichard, 2008, 2013; Ardelli et al., 2009).
To analyze gene expression, NGM agar plates were treated with
either 2.5 nM MOX or no drug and inoculated with 250 adult her-
maphrodite worms of each strain for each treatment (i.e., non-trea-
ted controls and MOX treated worms). Worms were removed from
plates every 30 min (i.e., 0.5 h, 1 h, 1.5 h, 2 h and 2.5 h) and total
RNA was extracted at each time point for use in real-time PCR anal-
ysis. The details of the real-time PCR protocol and gene expression
analysis were as described (Ardelli et al., 2009; Ardelli and
Prichard, 2013).
2.4. Microplate assay
Preliminary tests of motility and pharyngeal pumping were
conducted in 48 well plates using adult hermaphrodites of all
strains. A volume of 10 lL of worms (n = 50) in M9 Buffer, MOX
(2.5 nM, 5.0 nM and 10.0 nM) and inhibitors (2.5 nM, 5.0 nM and
10.0 nM) were distributed to the appropriate well of the plate.
Treatments included a control, MOX, an inhibitor, and MOX co-
administered with an inhibitor. After three hours, worms were
checked for pharyngeal pumping and movement using a Nikon
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majority of worms were moving or displayed pharyngeal pumping,
and negative if there was no movement or pharyngeal pumping.
The results of this pilot study indicated that there were differ-
ences in the effects of MOX on pharyngeal pumping and motility
in the wild-type, IVM-R and PGP deletion strains that are concen-
tration dependent. MOX alone did not affect phenotype in the
wild-type or IVM-R strain at any concentration tested for the three
hour time period used in this study; this was similar to a previous
study (Ardelli et al., 2009). However, incubation for longer periods
resulted in a loss of motility and pharyngeal pumping in the Bristol
N2. Based on these results further detailed analyses of motility (i.e.,
velocity and path length) and pharyngeal pumping were con-
ducted at 5.0 nM using agar plates as described below. The results
of the pilot study are reported in Supplementary Tables 1–3.
2.5. Macroplate assay
NGM agar plates were seeded with E. coli OP50 and controlled
for temperature, touch effects, light and developmental stage as
described (Ardelli et al., 2009; Ardelli and Prichard, 2013). To
assess motility of worms, plates were inoculated with 15.0 lL of
5.0 nM MOX, 5.0 nM of an inhibitor, or MOX co-administered with
an inhibitor (each at a concentration of 5.0 nM). Control plates
were not inoculated with MOX or an inhibitor. Plates were incu-
bated overnight at room temperature to allow bacteria to grow
and then seeded with 10 adult hermaphrodite worms for each
treatment. Motility and pharyngeal pumping were recorded after
three hours. The macroplate assay was repeated three times (i.e.,
three independent trails) with 10 worms measured per trial. Motil-
ity was determined using a QImaging Qicam interfaced with a
Nikon SMZ1500 microscope networked with a computer. Using
the program NIS Elements version 4.0, the movement of each
worm was recorded for one minute. Path velocity (px/s) and dis-
tance traveled (px) were determined. The number of pharyngeal
pumps of each worm was recorded for a period of one minute. Full
movement of the grinder to the back of the terminal bulb and
return to the initial position within the terminal bulb was consid-
ered one pharyngeal pump.
2.6. Data analysis
We determined if overall differences existed between pheno-
typic responses of control and MOX treated worms with an analy-
sis of variance (ANOVA). A Tukey’s Honest Signiﬁcant Difference
(HSD) test with Bonferroni adjustment was used for pairwise com-
parisons of the mean response to the different treatments. This was
to determine which of the treatments differed from the others and
at what time point the difference was detected. We controlled for
MOX exposure by testing treatments against negative controls (no
MOX or inhibitor) using Spearman’s Chi squares probability and
found all test contrasts to be signiﬁcant (results not shown). Thus
we are conﬁdent that any effects due to the addition of inhibitor
are real. Signiﬁcance for all statistical tests was taken at p < 0.05.3. Results
3.1. Transcriptional proﬁles of ABC systems genes following treatment
with MOX
The transcriptional proﬁles of 15 PGPs in the wild-type and the
IVM-R strain were determined after exposure to 2.5 nM MOX
(Fig. 1). The transcriptional proﬁle for each gene was determined
over 2.5 h beginning 30 min after introduction of worms to agar
plates, and for every 30 min thereafter, up to 2.5 h after drugexposure. Signiﬁcant differences in the transcriptional proﬁles
(indicated by an asterisk [⁄]) for these two strains were noted for
pgp-1 (2.5 h), pgp-5 (2.5 h), pgp-6 (1.5 and 2.5 h), pgp-12 (0.5, 1.5
and 2.5 h), pgp-14 (1.5 and 2.5 h) and pgp-15 (1.5 and 2.5 h). Signif-
icant differences were not detected for pgp-2, pgp-3, pgp-4, pgp-7,
pgp-8, pgp-9, pgp-10, pgp-11 and pgp-13 following treatment with
MOX (Fig. 1).3.2. Pharyngeal pumping
Fig. 2(A–E) shows the signiﬁcant results obtained for the pha-
ryngeal pump rate (pumps/minute) for C. elegans following treat-
ment with MOX alone, inhibitor alone or MOX administered in
combination with an inhibitor. The complete data set is shown in
Supplementary Fig. 1. Following treatment of the Bristol-N2
(MOX sensitive, wild-type) strain with MOX, the pharyngeal pump
rate was signiﬁcantly lower compared to the non-treated control,
but it did not cease (Fig. 2A). However, pharyngeal pumping
stopped following treatment of this strain with MOX in combina-
tion with an inhibitor (Fig. 2B–E).3.2.1. IVM-R (cross-resistant to MOX)
The IVM-R strain was created by introducing point mutations
into the alpha subunit genes avr-14, avr-15 and glc-1 (Dent et al.,
2000). These mutations did not affect the pump rate in this strain
as it was not signiﬁcantly different from that of the wild-type
(Fig. 2A). Treatment of the IVM-R strain with MOX either alone
or in combination with inhibitors lowered the pump rate however
it did not cease (Fig. 2B–E). For the majority of the inhibitors
administered alone or in combination with MOX, there was an
increased pump rate (e.g., verapamil, quinidine and colchicine)
when compared to the non-treated IVM-R control (indicated by
the short, red dotted line). These results are similar to those
observed in the wild-type strain.3.2.2. Pgp-2 and pgp-14 deletion strains
PGP-2 and PGP-14 are normally expressed in the pharynx (Zhao
et al., 2004). Disruption of these genes affected the pump rate and
it was signiﬁcantly higher in these strains than that of the wild-
type (Fig. 2A). Pumping ceased following administration of MOX
for the pgp-2 but not the pgp-14 deletion strain. Co-treatment of
the pgp-14 deletion strain with MOX and an inhibitor caused pha-
ryngeal pumping to cease, with the exception of quinidine, colchi-
cine and forskolin (2B–E). These results are different to those
observed for the wild-type strain.3.2.3. Pgp-8 and pgp-15 deletion strains
PGP-8 and PGP-15 are normally expressed in the neurons (Zhao
et al., 2004). Disruption of these genes affected the pump rate and
it was signiﬁcantly higher in these strains compared to the wild-
type strain (Fig. 2A); however pumping ceased following MOX
treatment.3.2.4. Pgp-1, pgp-5 and pgp-10 deletion strains
PGP-1, PGP-5 and PGP-10 are normally expressed in the intes-
tine (Zhao et al., 2004). Disruption of these genes resulted in a sig-
niﬁcantly higher pump rate in these strains when compared to that
of the wild-type (Fig. 2A). Following treatment with MOX, pump-
ing ceased in the pgp-1 and pgp-10 deletion strains, but not in
the pgp-5 strain, although it was signiﬁcantly reduced (Fig. 2A).
Similar to effects observed in the wild-type, treatment of the
pgp-5 deletion strain with MOX administered in combination with
an inhibitor caused pharyngeal pumping to cease (Fig. 2B–E).
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Fig. 1. Transcriptional proﬁle of 15 PGP genes in C. elegans wild-type and deletion strains following treatment with MOX. The ﬁgure shows the strain, expression site (Zhao
et al., 2004) and transcriptional proﬁle of each gene at 0.5 h, 1.5 h and 2.5 h after treatment with 2.5 nMMOX. The proﬁle of the wild-type strain is represented by a white bar
(h) and that of the IVM-R strain by a black bar (j). The Y-axis shows the fold over-expression compared with expression in the absence of MOX. Signiﬁcant differences in the
proﬁles between the two strains are indicated by an asterisk (⁄).
146 E.E. Bygarski et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 143–1513.2.5. Pgp-6, pgp-13, pgp-3, pgp-4, pgp-12 and pgp-7 deletion strains
Disruption of PGP-13 (expressed in intestine and amphids),
PGP-3 (expressed in the intestine and excretory cell) and PGP-4
and PGP-12 (both expressed in the excretory cell) had a signiﬁcant
effects on the pump rate (Fig. 2A), and it ceased following MOX
treatment. PGP-6 and PGP-7 are found in a four gene cluster with
PGP-5 and PGP-8 and are expressed in the intestines and amphids
(PGP-6) and the tail (PGP-7; Zhao et al., 2004). Disruption of PGP-6
and PGP-7 genes did not affect the normal non-treated pharyngeal
pump rate; however it ceased following treatment with MOX.3.3. Motility: path length and velocity
For motility, the parameters path length (px) and velocity (px/s)
were measured, however only results for velocity (Fig. 3A–E) are
reported as the patterns produced for path length and velocity
were similar (i.e., a signiﬁcant increase or decrease in velocity
was correlated with a signiﬁcant increase or decrease in path
length). Gene disruption did not affect velocity in pgp-14 and
pgp-15 deletion strains as it was not signiﬁcantly different from
the non-treated wild-type. For all other strains, the gene mutations
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the wild-type, the velocity was signiﬁcantly reduced following
treatment with MOX, but it did not cease (Fig. 3A). The exception
was the IVM-R strain in which there was no change in the velocity
following MOX treatment.
As the Bristol N2 (MOX sensitive, wild-type) strain was still
motile following treatment with MOX, a number of additional
experiments were performed where the strain was treated with
MOX in combination with a number of PGP inhibitors. For the 11
different treatment combinations, velocity was signiﬁcantly
reduced in this strain but it did not cease (Fig. 3B–E). Similar
results were obtained for the 14 mutant strains examined.Velocity (px
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In this study we report on two phenotypes, pharyngeal pump-
ing and velocity, in a MOX/IVM sensitive wild-type strain, an
IVM/MOX resistant strain and 13 PGP deletion strains in an effort
to understand the potential role of PGP in MOX resistance. Since
some nematodes resistant to IVM are also cross-resistant to
MOX, an understanding of the mechanism of resistance and
cross-resistance in different species of nematodes is important,
particularly as clinical trials have progressed to Phase 3 for MOX
to assess its efﬁcacy against O. volvulus (WHO, 2009), a parasite
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) or MOX administered in combination with an inhibitor (both at 5 nM). The x-axis
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es represent the mean ± standard deviation of the mutant strain without treatment.
to the web version of this article.)
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gested efﬂux of IVM by PGP as a protective or resistance conferring
mechanism (Ardelli and Prichard, 2008; James and Davey, 2009;
Dicker et al., 2011; Williamson et al., 2011; Lespine et al., 2012),
the aim of this study was to determine the contribution of PGPs
to the effects of MOX, using C. elegans as a model organism. The
majority of studies on PGPs and their role in drug resistance in
nematodes have focused on IVM with limited studies on role of
these transporters and MOX effects. While a number of the dele-
tion strains appear to be superﬁcially wild-type, the observations
on pharyngeal pumping and motility suggest that deletion of some
of the PGP genes has a measurable effect on phenotype. For exam-
ple, the normal non-treated pharyngeal pump rate for the deletion
strains pgp-1, pgp-2, pgp-3, pgp-5, pgp-10, pgp-12 and pgp-13 were
signiﬁcantly higher than that of the wild-type strain, suggesting
that deletion of these genes does affect feeding in these strains.
In contrast, where gene deletion increased the pharyngeal pump
rate, the opposite was observed with motility in that velocity
was signiﬁcantly lower in the deletion strains in comparison with
the wild-type. A study by Janssen et al. (2013) of the effects of PGP
gene deletion on C. elegans demonstrated an effect on development
in pgp-8, pgp-14 and pgp-11 deletion strains.
A study of GluCl genes in C. elegans suggested that the product
of the glc-2 gene may play a role in sensitivity to MOX, but not to
IVM, while the products of avr-14, avr-15 and glc-1 genes may be
important for the effects of IVM, but less so for MOX (Ardelli
et al., 2009). A recent study of the IVM-R strain used in this study
demonstrated increased sensitivity to IVM (i.e., paralysis or
reduced pharyngeal pumping) following co-administration of
IVM with verapamil, or actinomycin D, or daunorubicin, or colchi-
cine (Ardelli and Prichard, 2013). As these drugs are known inhib-
itors of PGP, it was suggested that the action of IVM is mediated by
receptors in addition to GluCls and likely includes members of the
ABC systems family, particularly PGPs (Ardelli and Prichard, 2013).
In the current study, co-administration of MOX with any inhibitor
caused pharyngeal pumping to cease while velocity was signiﬁ-
cantly reduced by some inhibitors in the wild-type strain (in the
three hour period used in this study). In the IVM-R strain, while
exposure to some inhibitors in combination with MOX reduced
motility and pharyngeal pumping, they did not cease. This suggests
that the product of the glc-2 gene, which is a b subunit (Laughton
et al., 1997), is more important for the effects of MOX than are the
products of the avr-14, avr-15 and glc-1 genes. In addition, PGPs
may play a role in MOX resistance, as sensitivity to MOX increased
following addition of a PGP inhibitor, however the effects were less
pronounced than for IVM. This is not surprising as MOX has a
weaker afﬁnity for PGP than the avermectins (Prichard et al.,
2012). However, the PGP inhibitors used can all have effects on
non-PGP targets, and the potentiation of the combination of the
inhibitor to MOX could be due to non-PGP effects caused by the
inhibitor.
PGP homologues are found across a number of species, from
microorganisms to humans (Higgins, 2001). Despite being found
in varying numbers in many species, the structure and function
of a typical PGP are similar and they confer an ‘‘innate resistance’’
against toxins. The activation of this defense mechanism in mam-
mals and nematodes is often observed as changes in expression
levels (Chin et al., 1990). There were differences in the expression
proﬁles of 15 PGP genes in the Bristol N2 and the IVM-R strains fol-
lowing treatment with MOX (present study) and IVM (Ardelli and
Prichard, 2013). Following 0.5 h of IVM treatment, there was a sig-
niﬁcant increase in the expression proﬁles of pgp-1, pgp-9, pgp-11,
pgp-12, pgp-13, pgp-14 and pgp-15 in the IVM-R strain while signif-
icant differences were only noted for pgp-12 after treatment with
MOX. Similarly, after 1.5 h of treatment, the IVM-R strain showed
increased expression of pgp-4, pgp-7, pgp-11, pgp-13, pgp-14 andpgp-15 with IVM, and of pgp-6, pgp-12, pgp-14 and pgp-15 with
MOX treatment. After 2.5 h, treatment with IVM induced increased
expression of pgp-4, pgp-7, pgp-11, pgp-14 and pgp-15 in the IVM-R
strain, and of pgp-1, pgp-5, pgp-6, pgp-12, pgp-14 and pgp-15 after
treatment with MOX. A study examining larval development in
the C. elegans wild-type and the 15 PGP deletion strains following
treatment with IVM suggested that pgp-11 and pgp-14were impor-
tant (Janssen et al., 2013). While there were a number of similar
PGP expression patterns induced in the IVM-R strain after treat-
ment with both MOX and IVM, there were also some unique
expression proﬁles noted. For example, a signiﬁcant increase in
expression was noted for pgp-6 (expressed in intestine [Zhao
et al., 2004]) following MOX treatment that was not induced by
IVM at any of the time points examined, while a signiﬁcant
increase in expression was noted for pgp-4 (expressed in excretory
cell), pgp-7 (expressed in tail), pgp-9 (expressed in pharynx and
intestine), pgp-11 (expressed in intestine and excretory cell) and
pgp-13 (expressed in intestine and amphids) following IVM treat-
ment that were not noted for MOX. A change in transporter activ-
ity, induced by changes in gene expression, can have an impact on
drug efﬁcacy and resistance Pajic et al., 2009; Gao et al., 2010;
Menez et al., 2012). The differences in PGP expression induced by
MOX and IVM suggest some differences in the mechanism of action
and efﬂux mechanisms that may contribute to resistance, as both
studies were conducted using the same IVM resistant strain of C.
elegans. As the main function of PGP is detoxiﬁcation, the results
of this study suggest that different detoxiﬁcation mechanisms
may be involved, as there was increased expression in some PGPs
that were unique to MOX and some that were unique to IVM.
Studies of mammals with PGPs that was either deleted or dis-
rupted showed increased sensitivity to IVM (Schinkel et al.,
1994). It is of interest that in Mdrab (/) double knock-out mice
there was an approximately 5-fold lower sensitivity to MOX toxic-
ity than to IVM toxicity (Ménez et al., 2012). A study examining C.
elegans strains that had all or portions of the multidrug resistance
associated protein (MRP) genes deleted demonstrated that disrup-
tion of the MRP genes caused less change in the motility phenotype
following MOX exposure compared with IVM exposure, suggesting
that the MRPs may play less of a role in protecting C. elegans from
MOX toxicity than they do in protecting the nematode from IVM
toxicity. In this study, the effect of deleting part of or the entire
PGP gene on sensitivity to MOX was examined in 13 PGP deletion
strains by measuring changes in velocity and pharyngeal pumping.
In terms of pharyngeal pumping, exposure to MOX caused pump-
ing to cease in all PGP deletion strains except for the pgp-5 and
pgp-14 deletion strains. Velocity was signiﬁcantly reduced but
did not cease in all of the PGP deletion strains following MOX treat-
ment. The characteristic phenotype associated with motility in
IVM exposed wild-type worms is a ‘‘hyperactivity’’ which peaks
at 1.5 h (Ardelli et al., 2009). Inactivation of pgp-2, pgp-5, pgp-6,
pgp-7, pgp-12 and pgp-13 resulted in increased sensitivity to IVM
and the magnitude of this increased sensitivity varied (Ardelli
and Prichard, 2013). Deletion of these genes resulted in an earlier
onset of paralysis in treated worms than was observed in treated
wild-type worms; pharyngeal pumping was not measured follow-
ing exposure to IVM in the PGP deletion strains (Ardelli and
Prichard, 2013). While the effects on velocity in a number of the
PGP deletion strains were similar after treatment with both MOX
(present study) and IVM (Ardelli and Prichard, 2013), there were
also some unique patterns (with the exception of deletion strains
pgp-1, pgp-3, pgp-8, pgp-10, pgp-14 and pgp-15 which were not
examined by Ardelli and Prichard (2013)). For example, disruption
of the pgp-2, pgp-5, pgp-12 and pgp-13 genes resulted in paralysis
following 2.5 h of IVM exposure, but worms were still motile
following exposure to MOX (although signiﬁcantly reduced). As
discussed previously (Ardelli and Prichard, 2013), pgp-12 is
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ter of duplicated genes in tandem with pgp-13, pgp-14 and pgp-15
(Zhao et al., 2004). As the excretory cell of C. elegans performs func-
tions analogous to the mammalian kidney, PGPs associated with
this cell would be expected to assist in toxin elimination. Targeted
disruption of pgp-12 could result in an inability to remove IVM and
perhaps metabolic waste products, resulting in an increased dis-
turbance to homeostasis, leading to a more pronounced paralysis.
It has been suggested that IVM is excreted from the mammalian
intestine through a PGP-dependent pathway, while MOX is mostly
excreted via a PGP-independent pathway (Kiki-Mvouaka et al.,
2010). The results of the current study are consistent with this
hypothesis as pgp-12 and pgp-13 deletion C. elegans strains were
more sensitive to IVM than to MOX.
The function of PGPs can be inhibited by substrates that are com-
petitive inhibitors (e.g., verapamil) or that block their function
directly. Treatment of MDR organisms with inhibitors restores drug
sensitivity (Molento and Prichard, 1999; Summers et al., 2004). We
explored the potential for PGP inhibition with substrates by expos-
ing C. eleganswild-type, IVM-R and PGP deletion strains to a number
of compounds that are known to interfere with PGP function. The
results are depicted in Figs. 2 (pharyngeal pumping), 3 (velocity)
and Supplementary Fig. 1 and are arranged based on the additional
mechanism of action of the compound (i.e., ion channels, tubulin,
DNA replication and enzymes). With pharyngeal pumping, the
majority of compounds administered in combination with MOX
inhibited the pharyngeal pump rate in the wild-type and PGP dele-
tion strains, but not the IVM-R. Verapamil is a calcium channel
blocker that is well documented as a viable PGP inhibitor in humans
and other mammals (Summers et al., 2004; Syvanen and
Hammarlund-Undenaes, 2010). When administered alone, verapa-
mil reduced the pump rate in all PGP deletion strains, and it ceased
in the pgp-2, pgp-4 and pgp-6 deletion strains. Following co-admin-
istration of verapamil with MOX pharyngeal pumping ceased in all
strains with the exception of the pgp-14 (expressed in pharynx) and
pgp-15 (expressed in neurons) deletion strains and the IVM-R strain.
This is in contrast to a similar study examining the effects of IVM
and verapamil on the IVM-R and wild-type strains (Ardelli and
Prichard, 2013). In that study, verapamil was the only inhibitor that
induced paralysis in both thewild-type and IVM-R strains when the
worms were exposed to IVM, though as expected, the wild-type
strain was more sensitive than the IVM-R strain. The observations
of this study are consistent with verapamil being a potent PGP
inhibitor in C. elegans. Similar to the results obtained following co-
administration of IVM with verapamil, there were concentrations
of MOX at which verapamil was able to induce paralysis of move-
ment and pharyngeal pumping in the wild-type and IVM-R strains
(see Supplementary Tables 1–3). A study examining the kinetics
of IVM and MOX in sheep, following co-administration of the drugs
with verapamil demonstrated an impact on IVM kinetics but not on
MOX (Molento et al., 2004).
Of interest were the pgp-6 and pgp-7 deletion strains. For the
pgp-7 deletion strain, all inhibitors, with the exception of verapa-
mil, had a stimulatory effect in that the pharyngeal pump rate sig-
niﬁcantly increased in comparison to the non-treated control,
however all inhibitors administered in combination with MOX
caused pharyngeal pumping to cease. The opposite effect was
observed in the pgp-6 deletion strain. With the exception of qui-
nine and actinomycin, all inhibitors, administered alone or in com-
bination, caused pharyngeal pumping to cease in this strain,
pumping ceased with quinine and actinomycin following co-
administration with MOX. Movement was less sensitive to the
effects of MOX, administered alone or in combination, for these
two strains. Many of the 60 C. elegans ABC transporter genes are
found in clusters and pairs of sister genes (Zhao et al., 2004). Six-
teen C. elegans ABC genes on the X chromosome are arranged intandem, forming two four-gene clusters and four two-gene clus-
ters. PGPs 6 and 7 are found in a four-gene cluster along with PGPs
5 and 8. We did ﬁnd a similar pattern of induction of expression for
these genes in both the wild-type and the IVM-R strain of C. elegans
when exposed to MOX. PGP-6 showed the greatest change in
expression in the N2 strain while PGP-7 showed the greatest
change in the IVM-R strain following exposure to MOX. PGP-6 is
expressed in the larval and adult intestine as well as the lateral
sensilla at the tip of the adult head (amphids), while PGP-7 is
expressed in the tail (Beuchner et al., 1999). The sensitivity of
the pgp-6 deletion strain to MOX (either administered alone or in
combination with inhibitors), as well as the signiﬁcantly increased
expression of the gene in the N2 strain following treatment with
MOX, suggests that PGP-6 may be important in protecting C. ele-
gans fromMOX toxicity. In a study of PGP-6 expression in C. elegans
following exposure to IVM, a signiﬁcant over-expression of PGP-6
was demonstrated (Ardelli and Prichard, 2013). It was suggested
that the signiﬁcant over-expression could help protect the nema-
todes from the effects of IVM because the sensory endings of the
extra pharyngeal neurons are in the amphids and drug uptake with
food or via the chemosensory amphids are important means by
which nematode cells become exposed to drugs (Bargmann and
Horvitz, 1991). Thus, the over-expression of PGPs in these tissues
could be expected if the worms use these pumps to remove the
drug from the intestinal cells and amphidial neurons. It is plausible
that a similar mechanism is operating in C. elegans with respect to
MOX and PGP-6.
We have shown that C. elegans may use PGP regulation as a
response mechanism to MOX. This response was measured in the
over-expression of several PGPs, in both susceptible wild-type
and the synthetically resistant IVM-R strains exposed to MOX.
The signiﬁcant changes in movement and pharyngeal pumping in
the IVM-R strain in the presence of compounds known to inhibit
or disrupt PGP function is consistent with the hypothesis that
MOX action is mediated in part by PGP transporter proteins. How-
ever, the compounds did not completely disrupt expression of
these phenotypic traits (within our 2.5 h study period), which indi-
cates that there are likely to be multiple avenues for MOX action
that may include receptors other than GluCls. If MOX resistance
was mediated solely by GluCls, then exposure to PGP inhibitors
should not have affected sensitivity to MOX. Targeted gene dele-
tion has shown that protection of C. elegans against MOX involves
complex mechanisms and depends in part on members of the PGP
gene family, particularly PGP-6. The results obtained in this study
are similar to those obtained using IVM (Ardelli and Prichard,
2013) however there were some important differences. The differ-
ences observed with respect to PGP may play a role in the differ-
ences seen in the expression of resistance to IVM and MOX.
However, the similarities observed are of concern as parasites
resistant to IVM show some degree but not complete cross-resis-
tance to MOX (see review by Prichard et al., 2012); this could
impact nematodes that are resistant to IVM, such as O. volvulus.
Further research is needed to determine the extent to which these
PGP transporters play a role in drug cross-resistance to IVM and
MOX in parasitic nematodes.
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